- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Payer Support Driving Lowering of Biosimilar-Related Health Care Costs
Experts address the need for lower costs of treatment, as well as ways payers can support patients with the use of biologics.
EP: 1.Utilizing Recently Approved Biosimilars in Clinical Practice
EP: 2.Transitioning to Biosimilars: Considerations for Providers and Payers
EP: 3.Navigating Challenges Associated with Biosimilars Across Various Disease States
EP: 4.Provider Acceptance Driving Confidence in Biosimilar Therapy
EP: 5.Decision-Making Process Surrounding Biosimilar Implementation
EP: 6.Biosimilar Administration Considerations Impacting Patient Experience
EP: 7.Initiating Biosimilar Treatment in Patients Without Previous Reference Biologic Experience
EP: 8.Switching Patients from Reference Product to Biosimilar
EP: 9.Defining Interchangeability and Switching in Biologics
EP: 10.Evolution of Auto-Substitution in Biosimilar Landscape
EP: 11.An Overview of Biosimilar Extrapolation During FDA Approval
EP: 12.Harnessing Indication-Specific Data on Biosimilars
EP: 13.Cost Savings Related to Biosimilars
EP: 14.Payers and PBMs Impacted by Biosimilar Integration
EP: 15.Payer Support Driving Lowering of Biosimilar-Related Health Care Costs
EP: 16.Patient Conversations: Managing Patient Expectations Regarding Biosimilars
EP: 17.Key Points of Emphasis Regarding Biosimilar Integration
This is a video synopsis/summary of a panel discussion involving Ryan Haumschild, PharmD, MS, MBA; Alice B. Gottlieb, MD, PhD; Bincy Abraham, MD, MS; Jamie T. Brogan, APRN; and Vibeke Strand, MD.
Haumschild asks Gottlieb how payers can support biosimilar utilization to lower health care costs beyond just acquisition costs. Gottlieb says payers and pharmacy benefit managers should focus less on segment profit and more on reducing patient costs.
Haumschild notes that integrated specialty pharmacies improve adherence and access. His study found 25% better adherence when patients fill within an integrated network. Onsite specialty pharmacy staff can assist with prior authorizations and injections during visits. Equitable access to integrated specialty pharmacies provides oversight improving outcomes and potentially lowering total costs.
Gottlieb agrees that an onsite specialty pharmacy facilitates a team approach for efficient prior authorization and improving the patient experience. Although her hospital assists patients if they must use an outside specialty pharmacy, they have an onsite team to maximize each patient visit.
Video synopsis is AI-generated and reviewed by AJMCÒ editorial staff.
Racial Differences in CA-125 Levels Tied to Ovarian Cancer Treatment Delays
April 17th 2025Black and American Indian women with ovarian cancer were less likely to have elevated cancer antigen 125 (CA-125) levels at diagnosis, resulting in delayed chemotherapy initiation and highlighting the need for more inclusive guidelines.
Read More
SGLT2 Inhibitors Show Renal Benefits in HF and CKD as Prescribers Target Uptake Gaps
April 15th 2025Abstracts featured at the National Kidney Foundation Spring Clinical Meeting highlighted the renoprotective benefits of SGLT2 inhibitors in heart failure and diabetic kidney disease while emphasizing the need for strategies to increase their uptake in primary care.
Read More
